The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects - Ruane, PJ; Brinson, C; Ramgopal, M; Ryan, R; Coate, B; Cho, M; Kakuda, TN; Anderson, D (HIV medicine, 2015)
Keywords: Adult; Adverse events; Aged; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - pharmacokinetics; Antiretroviral agents; Antiretroviral therapy; Body fat; Body Fat Distribution; Bone Density - drug effects; Bone mineral density; CD4 Lymphocyte Count; Darunavir; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; etravirine; Fat metabolism; Female; Glucose metabolism; HIV; HIV Infections - drug therapy; HIV-1 - drug effects; HIV‐1; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Immune response; Immunology; Labels; Lipid metabolism; Lipids; Lipids - blood; Male; Middle Aged; Nucleosides; nucleoside‐sparing; Pharmacodynamics; Pharmacokinetics; Pyridazines - administration & dosage; Pyridazines - pharmacokinetics; race; Respiratory tract; Respiratory tract infection; Ritonavir; Ritonavir - administration & dosage; Ritonavir - pharmacokinetics; RNA, Viral - drug effects; RNA-directed DNA polymerase; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics; Treatment Outcome; treatment‐experienced; Viral Load - drug effects; HIV-1; etravirine; darunavir; nucleoside-sparing; treatment-experienced; race